Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
NCT02943447 · Gilead Sciences · PHASE2 · terminated · last registry update 2020-09-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).” | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR1H4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-17Also stopped (withdrawn): Beijing 302 Hospital, Fenofibrate + UDCA (NCT02965911)
- 2021-09-05Also stopped (terminated): Novartis Pharmaceuticals, Tropifexor (LJN452) + Placebo (NCT02855164)
- 2021-07-29Results posted on the registry: Novartis Pharmaceuticals, Tropifexor (LJN452) + Placebo (NCT02855164)
- 2021-07-15Results posted on the registry: Gilead Sciences, Semaglutide + Firsocostat (NCT03987074)
- 2021-07-09Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Obeticholic Acid Tablets + UDCA (NCT04956328)
- 2021-06-14Phase 3 first posted: Hospital General Universitario de Alicante, Ursodeoxycholic Acid + Placebo (NCT04924868)
- 2021-05-18Results posted on the registry: Enanta Pharmaceuticals, Inc, EDP-305 1 mg + EDP-305 2.5 mg (NCT03394924)
- 2021-05-03Also stopped (terminated): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ursodeoxycholic Acid + Placebo (NCT00059202)
- 2021-04-20Also stopped (terminated): Vanderbilt University Medical Center, Ursodeoxycholic Acid + Placebos (NCT03201952)
- 2021-04-19Also stopped (suspended): Asan Medical Center, Fluvoxamine + Placebo (NCT04711863)
- 2021-04-08Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ursodeoxycholic Acid + Placebo (NCT00059202)
- 2021-03-24Also stopped (terminated): Boston University, a drug against NR1H4 (NCT03462940)
- 2021-02-17Results posted on the registry: NYU Langone Health, Ursodiol (NCT02748616)
- 2021-02-12Phase 3 first posted: Instituto Mexicano del Seguro Social, Bezafibrate 200 MG Oral Tablet + Placebo (NCT04751188)
- 2020-12-03Results posted on the registry: Gilead Sciences, SEL + FIR (NCT03449446)
- 2020-11-09Phase 3 first posted: Gilead Sciences, Seladelpar 10 mg + Placebo (NCT04620733)
- 2020-10-12Results posted on the registry: Gilead Sciences, Cilofexor + Placebo (NCT02654002)
- 2020-09-30Results posted on the registry: Gilead Sciences, Cilofexor (NCT02808312)
- 2020-09-09Phase 3 first posted: University of Oxford, Pancreatic Enzyme + Ursodeoxycholic acid (NCT04542473)
- 2020-08-31Phase 3 first posted: Children's Hospital of Fudan University, 4-Phenylbutyrate (NCT04531878)
- 2020-08-26Phase 3 first posted: Ipsen, Elafibranor 80mg + Placebo (NCT04526665)
- 2020-07-22Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Sincalide + Ursodiol (NCT00706381)
- 2020-03-30Results posted on the registry: Christopher Bowlus, MD, abatacept (NCT02078882)
- 2020-03-16Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy + Placebo of Bezafibrate in addition to standard UDCA therapy (NCT04309773)
- 2020-02-17Phase 3 first posted: Mirum Pharmaceuticals, Inc., Blinded CDCA 250 mg TID + Placebo (NCT04270682)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision